Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomized, open-label study of the effect of Herceptin plus Arimidex compared with Arimidex alone on progression-free survival in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
trastuzumab
BO16216
NCT00022672
HER2-positive metastatic breast cancer
Phase 3
 
July 2015

Powered by ideaPoint, Inc.